A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply?
Case report published in Semin Cardiothorac Vasc Anesth (2018)
Abstract
Anticoagulation for cardiopulmonary bypass (CPB) is required to prevent acute disseminated intravascular coagulation and clot formation within the bypass circuit. Unfractionated heparin is the standard anticoagulant for CPB due to its many advantages and long history of successful use. However, heparin has the unique drawback of triggering Heparin-PF4 (PF4) antibodies potentially leading to heparin-induced thrombocytopenia (HIT). We have limited data regarding reformation of antibodies if a patient has had a prior (remote) antibody production or full HIT. Patients with antiphospholipid antibodies undergoing CPB with unfractionated heparin have a high complication rate, even in the absence of HIT. Antiphospholipid antibodies have a multifaceted, cumulatively inhibitory effect on the normal anticoagulation armamentarium in vivo. Even more concerning is the possibility that antiphospholipid syndrome and HIT may be synergistic. We report a patient with risk factors for both thromboembolic (remote history of HIT and antiphospholipid syndrome) and hemorrhagic complications who underwent an aortic valve replacement and coronary artery bypass grafting on CPB using bivalirudin. We discuss the complex decision making regarding anticoagulant for CPB, particularly with regard to American College of Chest Physicians guidelines.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Case using bivalirudin for cardiopulmonary bypass in patient with remote HIT and antiphospholipid syndrome undergoing aortic valve replacement and CABG.
Why This Matters for Hirudotherapy
This case report describes a patient with both remote heparin-induced thrombocytopenia (HIT) and antiphospholipid syndrome who underwent aortic valve replacement and coronary artery bypass grafting on cardiopulmonary bypass, for which bivalirudin was used as the anticoagulant instead of standard unfractionated heparin. This is directly relevant to hirudotherapy and the leech secretome because bivalirudin is a direct thrombin inhibitor modeled on hirudin, the anticoagulant originally isolated from medicinal leech saliva, illustrating how a leech-derived pharmacological principle continues to address real clinical challenges when conventional heparin-based anticoagulation is contraindicated. The authors discuss the complex anticoagulant decision-making in light of American College of Chest Physicians guidelines. However, as a single case report, it does not establish the broader efficacy or safety of bivalirudin in this setting, and the management reflected this individual patient's combined thrombotic and hemorrhagic risk factors.
Citation
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply?.
Ibrahim W et al. · Semin Cardiothorac Vasc Anesth, 2018
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026